Insider buying last 90 days
No open-market insider purchases were filed for VTRS in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every VTRS insider filing, plotted on the chart in Gekko.Open VTRS in Gekko
NASDAQ: VTRS
Viatris (VTRS) Stock Analysis & Forecast
Sep 28 close
$18.27+0.44 (+2.5%)
Gekko Brief
AI summaryViatris this week draws attention on two fronts: litigation and analyst coverage. The company sued Novo Nordisk in Delaware federal court, seeking a ruling that its generic version of Wegovy would not infringe Novo Nordisk's patent on single-dose pen administration, effectively seeking permission to market a generic semaglutide product. Separately, Oppenheimer initiated coverage on Viatris with an outperform rating and a $25.00 price target, citing the company's improving base business, cost savings and late-stage pipeline. This follows an August 6 report in which Viatris posted adjusted EPS of $0.69 against a $0.62 estimate, with management raising 2026 guidance on the back of strength in Greater China and North America complex generics and transdermal products.
Shares closed at $18.27, up 2.5%, sitting above both the 50-day average of $16.90 and the 200-day average of $15.20, with the 52-week range spanning $9.47 to $18.39. The GekkoIndex reads 38.4, placing the stock in the Distribution zone, down 14.1 points over five sessions. Gekko Fair Value stands at $18.79, putting price 2.8% below that mark.
Earnings are next scheduled for 5 November 2026, 37 days out and outside a typical 20-day holding window; the prior report drew a -6.9% reaction despite the beat. No insider, Congress or unusual options activity appears in their respective windows, though four billionaire holders are noted. Seasonality over five years shows a 3.3% average 20-day return from this point, with gains in 3 of those years. Analyst consensus among 9 firms includes 5 buy, 3 hold and 1 sell ratings, with a consensus target of $19.40.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
Viatris price vs fair value
Close $18.27200-day averageGekko Fair Value $18.79
Viatris quick facts
- Market cap
- $21.28B
- P/E ratio
- —
- Forward P/E
- 6.4
- EPS, TTM
- −$0.38
- Revenue, TTM
- $14.74B
- Profit margin
- -2.8%
- Dividend yield
- 2.80%
- Beta
- 0.88
- Volume
- 12.38M avg 8.62M
- 1-year return
- +92.5%
- Typical daily move
- ±2.4%
- Typical 20-day move
- ±6.7%
- 50-day average
- $16.90
- 200-day average
- $15.20
- Next earnings
- Nov 5 before open
- Shares outstanding
- 1.15B
Viatris swing-trade checklist
Viatris scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed1 headwind
- Trendsupportive
Above 50 and 200-day
Close $18.27 is above the 50-day ($16.90) and 200-day ($15.20) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexheadwind
38.4, Distribution
Reading 38.4 is in the Distribution zone.
See the GekkoIndex - Fair valuemixed
2.8% below
Price is within 5% of Gekko Fair Value (2.8% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 37 days
Next report Nov 5, 2026, 37 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+3.3% on average
From this point in the calendar, the next 20 trading days averaged +3.3% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Viatris stock chart and price history
Viatris closed at $18.27 on Sep 28, 2026, +92.5% over the past year, inside a 52-week range of $9.47 to $18.39.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +8.2%
- 3 months
- +12.6%
- 6 months
- +40.0%
- 1 year
- +92.5%
The full VTRS chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open VTRS in Gekko
Follow Viatris through every session
Put VTRS on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track VTRS in GekkoFree for 7 days. No credit card required.
About Viatris
Viatris makes and supplies medicines and related health products worldwide, spanning branded drugs, generic and complex generic versions, biosimilars, and active pharmaceutical ingredients. Its medicines cover a wide span of conditions, from long-term illnesses to infectious disease, with biosimilar treatments aimed at areas such as cancer care, immune disorders, hormone conditions, eye disease, and skin conditions. Familiar names in its lineup include Lyrica, Lipitor, EpiPen, Viagra, and Celebrex, alongside biosimilar products like Fulphila, Ogivri, Hulio, and SEMGLEE.
The company is organized into four regional segments covering developed markets, Greater China, Japan/Australia/New Zealand, and emerging markets. It sells medicines in forms ranging from pills and injectables to raw ingredients, reaching pharmacies, wholesalers, hospitals, governments, and insurers through channels that include mail-order and specialty pharmacy networks. Beyond selling drugs, it offers services such as diagnostic clinics, health education, and digital tools, and it works with partners including Biocon, Theravance Biopharma, and Fujifilm Kyowa Kirin Biologics on development and licensing.
Viatris was founded in 1961 and is headquartered in Canonsburg, Pennsylvania. Its shares are listed on the NASDAQ under the ticker VTRS.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- viatris.com
Viatris GekkoIndex: the smart money zone
Viatris’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 38.4, in the Distribution zone, down 14.1 points over five sessions.
38.4Distribution
Down 14.1 points over five sessions, from the Neutral zone.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 32 | +1.0% | −0.2% | ||
| Accumulation | 205 | +0.1% | +0.3% | ||
| Neutral | 376 | +0.5% | +3.0% | ||
| Distribution (current zone) | 51 | +0.9% | −0.9% | ||
| Selling | 8 | Too few readings yet | |||
Average VTRS share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Distribution readings averaged +1.2% over 20 days. Past behaviour doesn’t guarantee future results.
Distribution zone: Institutions potentially offloading. About the five zones →
See every daily GekkoIndex reading plotted over the VTRS price, zone by zone.Track VTRS in Gekko
Is Viatris stock overvalued? Gekko Fair Value
Viatris trades 2.8% below Gekko Fair Value of $18.79, so the shares are about fair value on Gekko’s estimate.
Gekko’s own estimate of what Viatris shares are worth, recalculated every trading day.
$18.79
Gekko Fair Value, Sep 26, 2026
2.8% below fair value · About fair value
Gekko Fair Value on every chart, with the gap to price updating daily.Open VTRS in Gekko
Viatris insider and Congress trading
No open-market insider purchases were filed for Viatris, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in VTRS were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for VTRS, plotted on the chart in Gekko.Open VTRS in Gekko
Buybacks
Viatris has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $150.0M
- As a share of market cap
- 0.71%
From company filings.
Hedge funds and billionaires quarter ended Jun 30
4of the funds Gekko tracks hold VTRS.
3added0opened1trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
Viatris earnings: next date and track record
Viatris reports on Nov 5, 2026, before the open (37 days away), and beat the EPS estimate in 7 of its last 8 reports.
Next earnings report
Nov 5, 2026
Expected before the open, 37 days away
- EPS estimate
- $0.65
- Revenue estimate
- $3.80B
7 of 8reports beat the EPS estimate
±8.8%average move across the report
4 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 6, 2026 AI summary
- What they said
- Viatris reported a strong Q2 2026 with $3.8 billion in revenue (≈3.5% operational growth), adjusted EBITDA of $1.2 billion and adjusted EPS of $0.69, results management said exceeded expectations and allowed them to raise 2026 guidance. Commercial execution was highlighted across regions, led by Greater China, with strength in complex generics and transdermal products in North America and growth in developed market generics. Key pipeline and regulatory milestones include FDA approval of Gwyn Lo (once-weekly transdermal contraceptive) with launch planned later in 2026, ongoing NDA review for fast-acting meloxicam with an expected PDUFA year-end, positive Phase III results for Nefecon in Japan, and Phase III programs for selatogrel and cenerimod on track with readouts expected in 2027. Management emphasized execution on an enterprise-wide strategic review delivering operating leverage and cost containment, ongoing remediation at the Nashik manufacturing site after fire and inspection observations, and active M&A and capital allocation including potential buybacks/dividends. Confidence about China as a durable growth engine was tempered by potential provincial-level policy changes that could mute hospital-channel growth in H2. Overall tone was constructive and confident about the strategy and near-term catalysts, while acknowledging discrete operational and policy risks.
- Guidance
- Management said it has raised its 2026 outlook across key financial metrics (revenue and adjusted EBITDA) based on H1 strength; at the midpoint management indicated revenue was raised by about $50 million and adjusted EBITDA by about $100 million relative to prior guidance. Management expects multiple regulatory milestones and launches in the coming quarters (Gwyn Lo launch later in 2026; PDUFA for fast-acting meloxicam toward year-end). Selatogrel and cenerimod Phase III readouts are expected in 2027. No detailed numeric full-year guidance ranges were provided on the call beyond the statements above.
- Risks flagged
- Nashik manufacturing fire and FDA inspection observations requiring remediation (supply impacts in H2 2026); potential Chinese provincial-level policy changes affecting hospital procurement channels (could mute China growth); heightened competition in certain North America products and established brands; possible U.S. generic tariffs (policy details unclear); clinical and regulatory risk for pipeline programs (selatogrel, cenerimod, meloxicam); supply constraints for high-demand products (e.g., estradiol patches).
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 6, 2026 | $0.69 est $0.62 | $3.76B est $3.68B | −6.9% |
| May 7, 2026 | $0.59 est $0.50 | $3.52B est $3.36B | +7.6% |
| Feb 26, 2026 | $0.57 est $0.52 | $3.70B est $3.53B | −7.2% |
| Nov 6, 2025 | $0.67 est $0.62 | $3.76B est $3.62B | −5.9% |
| Aug 7, 2025 | $0.62 est $0.56 | $3.58B est $3.47B | +10.9% |
| May 8, 2025 | $0.50 est $0.49 | $3.25B est $3.24B | +2.0% |
| Feb 27, 2025 | $0.54 est $0.57 | $3.53B est $3.60B | −17.9% |
| Nov 7, 2024 | $0.75 est $0.68 | $3.74B est $3.72B | +11.6% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Viatris stock forecast and analyst price targets
Analysts’ average 12-month price target for Viatris is $19.40, +6.2% from the last close, from 9 firms rating the stock in the last 90 days.
$19.40consensus 12-month target, +6.2% from the last close
Now $18.27Avg $19.40
Low $13High $25
Each firm’s latest rating in the last 90 days: 9 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 23 | Oppenheimer | $25 | +36.8% |
| Sep 16 | Piper Sandler | $13 | −28.8% |
| Sep 9 | Leerink Partners | $20 | +9.5% |
| Sep 8 | Argus Research | $20 | +9.5% |
| Aug 17 | Barclays | $22 | +20.4% |
−0.9%average 20-day move after past Distribution readings
+3.3%average move over the next 20 trading days in the last 5 years
±2.4%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Viatris seasonality: the next 20 trading days
Over the next 20 trading days from Sep 26, Viatris averaged +3.3% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +1.5% | 3 of 5 |
| Next 10 trading days | +0.7% | 3 of 5 |
| Next 15 trading days | +3.8% | 3 of 5 |
| Next 20 trading days | +3.3% | 3 of 5 |
| Next 30 trading days | +7.6% | 4 of 5 |
For scale, VTRS’s typical 20-trading-day move in either direction is about 6.7%.
Viatris market cap and key statistics
Viatris’s market cap is $21.28B and revenue of $14.74B over the last twelve months.
Valuation
- Market cap
- $21.28B
- Forward P/E
- 6.4
- EPS, TTM
- −$0.38
- Gekko Fair Value
- $18.79
Trading
- Volume
- 12.38M
- Avg volume, 20 days
- 8.62M
- 52-week high
- $18.39
- 52-week low
- $9.47
- Shares outstanding
- 1.15B
Financials
- Revenue, TTM
- $14.74B
- Profit margin
- -2.8%
- Return on equity
- -2.7%
- Quarterly earnings growth, YoY
- −70.6%
Risk and income
- Beta
- 0.88
- Typical daily move
- ±2.4%
- Typical 20-day move
- ±6.7%
- Dividend yield
- 2.80%
Viatris stock news this week
Coverage of Viatris this week reads positive: 3 positive, 2 neutral and 1 negative headlines.
- Viatris sues Novo Nordisk over generic Wegovy patent disputeYahoo Finance, Sep 25
- Viatris sues Novo Nordisk, seeks to market generic WegovySeeking Alpha, Sep 25
- Oppenheimer initiates Viatris stock with outperform rating By Investing.comInvesting.com Nigeria, Sep 24
- How Viatris Inc. (VTRS) Affects Rotational Strategy TimingStock Traders Daily, Sep 24
- Oppenheimer initiates Viatris stock with outperform ratingInvesting.com, Sep 23
- Viatris Inc. (VTRS) Stock Analysis: Exploring A 10.78% Upside With Strategic CollaborationsDirectorsTalk Interviews, Sep 21
Viatris peers
Viatris’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 17.9% above |
| JNJJohnson & Johnson | Neutral | 0.5% above |
| ABBVAbbVie | Neutral | 23.3% above |
| MRKMerck | Neutral | 4.2% below |
| AZNAstraZeneca | Neutral | 39.9% below |
| PFEPfizer | Neutral | 4.0% below |
A peer links to its own page where one exists.
Viatris stock FAQ
What is Viatris’s market cap?
Viatris’s market cap is $21.28B at the Sep 28, 2026 close of $18.27, with 1.15B shares outstanding.
What is the Viatris stock forecast?
The consensus analyst 12-month price target for Viatris is $19.40, +6.2% from the last close. Of the 9 firms that rated the stock in the last 90 days, 5 rate it a buy, 3 a hold and 1 a sell. Gekko doesn’t publish price predictions of its own.
Is Viatris stock overvalued or undervalued?
On Gekko’s estimate Viatris is about fair value: the Sep 28, 2026 close of $18.27 is 2.8% below Gekko Fair Value of $18.79. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Viatris report earnings next?
Viatris is expected to report on Nov 5, 2026, before the market opens (37 days away). Analysts expect earnings of $0.65 per share on revenue of $3.80B. Viatris beat the earnings estimate in 7 of its last 8 reports, moving 8.8% on average across the report.
What is Viatris’s 52-week high and low?
Viatris’s 52-week high is $18.39 and its 52-week low is $9.47; it closed at $18.27 on Sep 28, 2026, +92.5% over the past year.
Is Viatris stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (trend, earnings risk and seasonality), 1 as mixed (fair value) and 1 as a headwind (gekkoindex). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Viatris the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.